CARA
Price:
$5.32
Market Cap:
$36.31M
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and ...[Read more]
Industry
Biotechnology
IPO Date
2014-01-31
Stock Exchange
NASDAQ
Ticker
CARA
According to Cara Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -115.90%. This represents a change of -309.99% compared to the average of 55.20% of the last 4 quarters.
The mean historical ROE of Cara Therapeutics, Inc. over the last ten years is 316.20%. The current -115.90% ROE has changed -136.65% with respect to the historical average. Over the past ten years (40 quarters), CARA's ROE was at its highest in in the December 2024 quarter at 167.19%. The ROE was at its lowest in in the June 2024 quarter at -172.58%.
Average
316.20%
Median
27.95%
Minimum
-38.87%
Maximum
1.54%
Discovering the peaks and valleys of Cara Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 5.42%
Maximum Annual ROE = 1.54%
Minimum Annual Increase = -1250.89%
Minimum Annual ROE = -38.87%
| Year | ROE | Change |
|---|---|---|
| 2024 | 1.54% | 5.42% |
| 2023 | 27.95% | -38.70% |
| 2022 | 45.60% | -217.30% |
| 2021 | -38.87% | -1250.89% |
The current ROE of Cara Therapeutics, Inc. (CARA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
538.83%
5-year avg
316.20%
10-year avg
316.20%
Cara Therapeutics, Inc.’s ROE is greater than Omega Therapeutics, Inc. (-173.25%), greater than Turnstone Biologics Corp. (-171.86%), less than Channel Therapeutics Corporation (243.75%), less than Biora Therapeutics, Inc. (12.18%), greater than COSCIENS Biopharma Inc. (-149.40%), greater than TNF Pharmaceuticals, Inc. (-48.34%), greater than IMV Inc. (-489.29%), greater than CervoMed Inc. (-59.15%), less than Apexigen, Inc. (48.27%), less than Kineta, Inc. (71.50%),
| Company | ROE | Market cap |
|---|---|---|
| -173.25% | $7.90M | |
| -171.86% | $8.21M | |
| 243.75% | $8.90M | |
| 12.18% | $994.99K | |
| -149.40% | $6.65M | |
| -48.34% | $9.18M | |
| -489.29% | $117.00 | |
| -59.15% | $73.10M | |
| 48.27% | $9.57M | |
| 71.50% | $7.05M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cara Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cara Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Cara Therapeutics, Inc.'s ROE?
How is the ROE calculated for Cara Therapeutics, Inc. (CARA)?
What is the highest ROE for Cara Therapeutics, Inc. (CARA)?
What is the 3-year average ROE for Cara Therapeutics, Inc. (CARA)?
What is the 5-year average ROE for Cara Therapeutics, Inc. (CARA)?
How does the current ROE for Cara Therapeutics, Inc. (CARA) compare to its historical average?